CDNA
CareDx Inc is a commercial stage company. The Company develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient\'s lifetime.
CareDx, Inc. (CDNA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C- (1.9) | C (2.2) | B- (2.9) | B+ (3.8) | C+ (2.6) | C+ (2.7) |
| 2026-11-04 | C- (1.9) | C (2.2) | B- (2.9) | A- (3.9) | C+ (2.7) | C+ (2.7) |
| 2026-10-28 | C- (1.9) | C+ (2.5) | B- (2.9) | A (4.5) | C+ (2.7) | B- (2.9) |
| 2026-10-21 | C- (1.9) | C+ (2.5) | B- (2.9) | A- (4.1) | C+ (2.6) | C+ (2.8) |
| 2026-10-14 | C- (1.9) | C+ (2.5) | B- (2.9) | A+ (4.9) | C+ (2.6) | B- (3.0) |